Your browser doesn't support javascript.
loading
The utility of thrombophilia and hematologic screening in live liver donation.
Naymagon, Leonard; Tremblay, Douglas; Facciuto, Marcelo; Lapointe Rudow, Dianne; Schiano, Thomas.
Afiliación
  • Naymagon L; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Tremblay D; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Facciuto M; Division of Liver Diseases, Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Lapointe Rudow D; Division of Liver Diseases, Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Schiano T; Division of Liver Diseases, Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Clin Transplant ; 35(1): e14159, 2021 01.
Article en En | MEDLINE | ID: mdl-33222303
BACKGROUND: Most centers perform some degree of hematologic screening, including thrombophilia testing, on prospective live liver donors. The nature and extent of such screens are not standardized, and there is limited evidence regarding hematologic risk stratification. METHODS AND RESULTS: We present an experience of hematologic screening among prospective liver donors. Five-hundred-eightyfour patients were screened for liver donation between 1/2013 and 1/2020, of whom 156 (27%) proceeded to donor hepatectomy. Thirty-three of 428 (8%) declined patients were excluded for hematologic indications. Hematologic indications were the 2nd most frequent medical indications for exclusion (trailing only hepatologic indications). The most common reason for hematologic exclusion was concern regarding thrombophilia. Nevertheless, 21 patients with evidence of possible thrombophilia proceeded to donor hepatectomy, and none incurred hematologic complications. Similarly, seven patients with screening findings concerning for increased bleeding risk (most often thrombocytopenia) underwent donor hepatectomy without hematologic complication. Three of 156 (2%) of patients who underwent donor hepatectomy incurred a hematologic complication (all thrombotic, none fatal). None of these patients had any evident hematologic risk factor on screening. CONCLUSION: This study underscores the difficulty of hematologic risk stratification among prospective living donors, however, suggests that some patients with relatively mild risk factors may be safe for donation.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Trasplante de Hígado / Trombofilia Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Risk_factors_studies / Screening_studies Límite: Humans Idioma: En Revista: Clin Transplant Asunto de la revista: TRANSPLANTE Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Trasplante de Hígado / Trombofilia Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Risk_factors_studies / Screening_studies Límite: Humans Idioma: En Revista: Clin Transplant Asunto de la revista: TRANSPLANTE Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos